Search results
-
Professor James Brenton
... in resistance has been to develop novel phase II clinical trials with sequential collection and profiling of ovarian cancer tissues ...
-
Dr Massimiliano di Pietro
... recent multi-centre studies led by our group (TIME and ACE-B trials) have demonstrated that it is possible to increase diagnostic accuracy ...
-
Dr Michael Gattens
... am principal investigator for a number of national leukaemia trials, and coinvestigator for trials of new haemophilia factor concentrates in paediatric haemophilia ...
-
Dr Phil Jewsbury
... pre-clinical candidate drugs to proof-of-concept Phase 2 trials. Currently a Senior Project Director in AstraZeneca Oncology ...
-
Dr Richard Baird
Early phase clinical trials, including expertise in: - first-in-human studies & drug combination trials - new small molecule & antibody therapeutics - development of ... cancer therapeutics. Investigator-initiated clinical trials funded by: - Cancer Research UK - EU HORIZON 2020 - AntiCancer ...
-
Professor Richard Gilbertson
... Program and founding Director of the Molecular Clinical Trials Core before being appointed as the Comprehensive Cancer Center Director, ...
-
Mr Richard Skells
... studies coordinated by CCTU and Cambridge Cancer Trials Centre. ...
-
Professor Robert Rintoul
... at Royal Papworth Hospital and Director of the Papworth Trials Unit Collaboration. He is co-lead of the CRUK Cambridge Centre Thoracic ... Rintoul’s research is focused around clinical trials, translational research and tissue banking in malignant mesothelioma and ...
-
Dr Robert Thomas
... completed and published a number of national research trials including; an evaluation of the impact of exercise in relation to ...
-
Dr Tim Mitchell
... CRT Pioneer Fund. This programme will start Phase 1 clinical trials at the Royal Marsden Hospital in June 2016. SKIL® (Sareum Kinase ...
-
Dr Helen Hatcher
... and psychological impacts of cancer. She is a member of the NCRN sarcoma clinical studies group and lead investigator in several ...
-
Dr Hanna Najgebauer
Open Targets Postdoctoral Fellow responsible for the development of new algorithms and computational tools for scoring cancer in vitro models based on their clinical relevance and covered genomic heterogeneity observed in primary disease.
